Cargando…

Cardio-Oncology in the COVID Era (Co & Co): The Never Ending Story

The pathophysiology of some non-communicable diseases (NCDs) such as hypertension, cardiovascular disease (CVD), diabetes, and cancer includes an alteration of the endothelial function. COVID-19 is a pulmonary and vascular disease with a negative impact on patients whose damaged endothelium is parti...

Descripción completa

Detalles Bibliográficos
Autores principales: Bisceglia, Irma, Canale, Maria Laura, Gallucci, Giuseppina, Turazza, Fabio Maria, Lestuzzi, Chiara, Parrini, Iris, Russo, Giulia, Maurea, Nicola, Quagliariello, Vincenzo, Oliva, Stefano, Di Fusco, Stefania Angela, Lucà, Fabiana, Tarantini, Luigi, Trambaiolo, Paolo, Moreo, Antonella, Geraci, Giovanna, Gabrielli, Domenico, Gulizia, Michele Massimo, Oliva, Fabrizio, Colivicchi, Furio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831543/
https://www.ncbi.nlm.nih.gov/pubmed/35155636
http://dx.doi.org/10.3389/fcvm.2022.821193
_version_ 1784648528016965632
author Bisceglia, Irma
Canale, Maria Laura
Gallucci, Giuseppina
Turazza, Fabio Maria
Lestuzzi, Chiara
Parrini, Iris
Russo, Giulia
Maurea, Nicola
Quagliariello, Vincenzo
Oliva, Stefano
Di Fusco, Stefania Angela
Lucà, Fabiana
Tarantini, Luigi
Trambaiolo, Paolo
Moreo, Antonella
Geraci, Giovanna
Gabrielli, Domenico
Gulizia, Michele Massimo
Oliva, Fabrizio
Colivicchi, Furio
author_facet Bisceglia, Irma
Canale, Maria Laura
Gallucci, Giuseppina
Turazza, Fabio Maria
Lestuzzi, Chiara
Parrini, Iris
Russo, Giulia
Maurea, Nicola
Quagliariello, Vincenzo
Oliva, Stefano
Di Fusco, Stefania Angela
Lucà, Fabiana
Tarantini, Luigi
Trambaiolo, Paolo
Moreo, Antonella
Geraci, Giovanna
Gabrielli, Domenico
Gulizia, Michele Massimo
Oliva, Fabrizio
Colivicchi, Furio
author_sort Bisceglia, Irma
collection PubMed
description The pathophysiology of some non-communicable diseases (NCDs) such as hypertension, cardiovascular disease (CVD), diabetes, and cancer includes an alteration of the endothelial function. COVID-19 is a pulmonary and vascular disease with a negative impact on patients whose damaged endothelium is particularly vulnerable. The peculiar SARS-CoV-2-induced “endothelitis” triggers an intriguing immune-thrombosis that affects both the venous and arterial vascular beds. An increased liability for infection and an increased likelihood of a worse outcome have been observed during the pandemic in patients with active cancer and in cancer survivors. “Overlapping commonalities” between COVID-19 and Cardio-Oncology have been described that include shared phenotypes of cardiovascular toxicities such as left ventricular dysfunction, ischemic syndromes, conduction disturbances, myocarditis, pericarditis and right ventricular failure; shared pathophysiologic mechanisms such as inflammation, release of cytokines, the renin-angiotensin-aldosterone-pathway, coagulation abnormalities, microthrombosis and endothelial dysfunction. For these features and for the catalyst role of NCDs (mainly CVD and cancer), we should refer to COVID-19 as a “syndemic.” Another challenging issue is the persistence of the symptoms, the so-called “long COVID” whose pathogenesis is still uncertain: it may be due to persistent multi-organ viral attacks or to an abnormal immune response. An intensive vaccination campaign is the most successful pharmacological weapon against SARS-CoV-2, but the increasing number of variants has reduced the efficacy of the vaccines in controlling SARS-CoV-2 infections. After a year of vaccinations we have also learned more about efficacy and side-effects of COVID-19 vaccines. An important byproduct of the COVID-19 pandemic has been the rapid expansion of telemedicine platforms across different care settings; this new modality of monitoring cancer patients may be useful even in a post pandemic era. In this paper we analyze the problems that the cardio-oncologists are facing in a pandemic scenario modified by the extensive vaccination campaign and add actionable recommendations derived from the ongoing studies and from the syndemic nature of the infection.
format Online
Article
Text
id pubmed-8831543
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88315432022-02-12 Cardio-Oncology in the COVID Era (Co & Co): The Never Ending Story Bisceglia, Irma Canale, Maria Laura Gallucci, Giuseppina Turazza, Fabio Maria Lestuzzi, Chiara Parrini, Iris Russo, Giulia Maurea, Nicola Quagliariello, Vincenzo Oliva, Stefano Di Fusco, Stefania Angela Lucà, Fabiana Tarantini, Luigi Trambaiolo, Paolo Moreo, Antonella Geraci, Giovanna Gabrielli, Domenico Gulizia, Michele Massimo Oliva, Fabrizio Colivicchi, Furio Front Cardiovasc Med Cardiovascular Medicine The pathophysiology of some non-communicable diseases (NCDs) such as hypertension, cardiovascular disease (CVD), diabetes, and cancer includes an alteration of the endothelial function. COVID-19 is a pulmonary and vascular disease with a negative impact on patients whose damaged endothelium is particularly vulnerable. The peculiar SARS-CoV-2-induced “endothelitis” triggers an intriguing immune-thrombosis that affects both the venous and arterial vascular beds. An increased liability for infection and an increased likelihood of a worse outcome have been observed during the pandemic in patients with active cancer and in cancer survivors. “Overlapping commonalities” between COVID-19 and Cardio-Oncology have been described that include shared phenotypes of cardiovascular toxicities such as left ventricular dysfunction, ischemic syndromes, conduction disturbances, myocarditis, pericarditis and right ventricular failure; shared pathophysiologic mechanisms such as inflammation, release of cytokines, the renin-angiotensin-aldosterone-pathway, coagulation abnormalities, microthrombosis and endothelial dysfunction. For these features and for the catalyst role of NCDs (mainly CVD and cancer), we should refer to COVID-19 as a “syndemic.” Another challenging issue is the persistence of the symptoms, the so-called “long COVID” whose pathogenesis is still uncertain: it may be due to persistent multi-organ viral attacks or to an abnormal immune response. An intensive vaccination campaign is the most successful pharmacological weapon against SARS-CoV-2, but the increasing number of variants has reduced the efficacy of the vaccines in controlling SARS-CoV-2 infections. After a year of vaccinations we have also learned more about efficacy and side-effects of COVID-19 vaccines. An important byproduct of the COVID-19 pandemic has been the rapid expansion of telemedicine platforms across different care settings; this new modality of monitoring cancer patients may be useful even in a post pandemic era. In this paper we analyze the problems that the cardio-oncologists are facing in a pandemic scenario modified by the extensive vaccination campaign and add actionable recommendations derived from the ongoing studies and from the syndemic nature of the infection. Frontiers Media S.A. 2022-01-28 /pmc/articles/PMC8831543/ /pubmed/35155636 http://dx.doi.org/10.3389/fcvm.2022.821193 Text en Copyright © 2022 Bisceglia, Canale, Gallucci, Turazza, Lestuzzi, Parrini, Russo, Maurea, Quagliariello, Oliva, Di Fusco, Lucà, Tarantini, Trambaiolo, Moreo, Geraci, Gabrielli, Gulizia, Oliva and Colivicchi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Bisceglia, Irma
Canale, Maria Laura
Gallucci, Giuseppina
Turazza, Fabio Maria
Lestuzzi, Chiara
Parrini, Iris
Russo, Giulia
Maurea, Nicola
Quagliariello, Vincenzo
Oliva, Stefano
Di Fusco, Stefania Angela
Lucà, Fabiana
Tarantini, Luigi
Trambaiolo, Paolo
Moreo, Antonella
Geraci, Giovanna
Gabrielli, Domenico
Gulizia, Michele Massimo
Oliva, Fabrizio
Colivicchi, Furio
Cardio-Oncology in the COVID Era (Co & Co): The Never Ending Story
title Cardio-Oncology in the COVID Era (Co & Co): The Never Ending Story
title_full Cardio-Oncology in the COVID Era (Co & Co): The Never Ending Story
title_fullStr Cardio-Oncology in the COVID Era (Co & Co): The Never Ending Story
title_full_unstemmed Cardio-Oncology in the COVID Era (Co & Co): The Never Ending Story
title_short Cardio-Oncology in the COVID Era (Co & Co): The Never Ending Story
title_sort cardio-oncology in the covid era (co & co): the never ending story
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831543/
https://www.ncbi.nlm.nih.gov/pubmed/35155636
http://dx.doi.org/10.3389/fcvm.2022.821193
work_keys_str_mv AT biscegliairma cardiooncologyinthecovideracocotheneverendingstory
AT canalemarialaura cardiooncologyinthecovideracocotheneverendingstory
AT galluccigiuseppina cardiooncologyinthecovideracocotheneverendingstory
AT turazzafabiomaria cardiooncologyinthecovideracocotheneverendingstory
AT lestuzzichiara cardiooncologyinthecovideracocotheneverendingstory
AT parriniiris cardiooncologyinthecovideracocotheneverendingstory
AT russogiulia cardiooncologyinthecovideracocotheneverendingstory
AT maureanicola cardiooncologyinthecovideracocotheneverendingstory
AT quagliariellovincenzo cardiooncologyinthecovideracocotheneverendingstory
AT olivastefano cardiooncologyinthecovideracocotheneverendingstory
AT difuscostefaniaangela cardiooncologyinthecovideracocotheneverendingstory
AT lucafabiana cardiooncologyinthecovideracocotheneverendingstory
AT tarantiniluigi cardiooncologyinthecovideracocotheneverendingstory
AT trambaiolopaolo cardiooncologyinthecovideracocotheneverendingstory
AT moreoantonella cardiooncologyinthecovideracocotheneverendingstory
AT geracigiovanna cardiooncologyinthecovideracocotheneverendingstory
AT gabriellidomenico cardiooncologyinthecovideracocotheneverendingstory
AT guliziamichelemassimo cardiooncologyinthecovideracocotheneverendingstory
AT olivafabrizio cardiooncologyinthecovideracocotheneverendingstory
AT colivicchifurio cardiooncologyinthecovideracocotheneverendingstory